Biosimilars (e.g., Semaglutide)
Type 2 Diabetes/Obesity
CommercialActive
Key Facts
About Phenotypeca
Phenotypeca is a private, platform-based biotechnology company developing optimized yeast strains for recombinant protein manufacturing. Its patented QTL (Quantitative Trait Locus) strain optimization technology uses large-scale breeding and whole-genome screening to evolve strains with superior yield, stability, and processing characteristics. The company generates revenue by licensing ready-to-scale strains for biosimilars and peptides, and by providing custom strain engineering services to partners. It appears to be in an early-revenue stage, supported by project work including a grant from the Bill & Melinda Gates Foundation.
View full company profileTherapeutic Areas
Other Type 2 Diabetes/Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Semaglutide/Tirzepatide Intermediates | Sinopeg | Commercial/Platform |
| HS-10511 | Hansoh Pharma | Phase I |
| IBI-362 | Innovent Biologics | Phase 3 |